Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study

Anastasios Stathis; Ian W. Flinn; Sumit Madan; Kami Maddocks; Arnold Freedman; Steven Weitman; Emanuele Zucca; Mihaela C. Munteanu; M. Lia Palomba

doi:10.1007/s10637-018-0570-4

Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study

Investigational New Drugs ◽

10.1007/s10637-018-0570-4 ◽

2018 ◽

Vol 36 (5) ◽

pp. 869-876 ◽

Cited By ~ 10

Author(s):

Anastasios Stathis ◽

Ian W. Flinn ◽

Sumit Madan ◽

Kami Maddocks ◽

Arnold Freedman ◽

...

Keyword(s):

Phase I ◽

B Cell ◽

Hodgkin Lymphoma ◽

Dose Escalation ◽

Phase I Study ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Non Hodgkin Lymphoma ◽

Antibody Drug

Download Full-text

A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-19-0711 ◽

2019 ◽

Vol 25 (23) ◽

pp. 6986-6994 ◽

Cited By ~ 19

Author(s):

Brad S. Kahl ◽

Mehdi Hamadani ◽

John Radford ◽

Carmelo Carlo-Stella ◽

Paolo Caimi ◽

...

Keyword(s):

Phase I ◽

B Cell ◽

Hodgkin Lymphoma ◽

Phase I Study ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Non Hodgkin Lymphoma ◽

Antibody Drug

Download Full-text

Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-16-0772 ◽

2016 ◽

Vol 23 (5) ◽

pp. 1167-1176 ◽

Cited By ~ 41

Author(s):

Ranjana H. Advani ◽

Daniel Lebovic ◽

Andy Chen ◽

Mark Brunvand ◽

Andre Goy ◽

...

Keyword(s):

Phase I ◽

B Cell ◽

Hodgkin Lymphoma ◽

Phase I Study ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Non Hodgkin Lymphoma ◽

Antibody Drug

Download Full-text

The effect of SGN-75, a novel antibody–drug conjugate (ADC), in treatment of patients with renal cell carcinoma (RCC) or non-Hodgkin lymphoma (NHL): A phase I study.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.3071 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 3071-3071 ◽

Cited By ~ 5

Author(s):

J. A. Thompson ◽

A. Forero-Torres ◽

E. I. Heath ◽

S. M. Ansell ◽

S. K. Pal ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Phase I ◽

Cell Carcinoma ◽

Hodgkin Lymphoma ◽

Renal Cell ◽

Phase I Study ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Non Hodgkin Lymphoma ◽

Antibody Drug

Download Full-text

Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-21-3261 ◽

2022 ◽

pp. clincanres.3261.2021

Author(s):

Alex F. Herrera ◽

Manish R. Patel ◽

John M. Burke ◽

Ranjana Advani ◽

Bruce D. Cheson ◽

...

Keyword(s):

B Cell ◽

Hodgkin Lymphoma ◽

Dose Escalation ◽

Phase 1 ◽

Antibody Drug Conjugate ◽

Dose Escalation Study ◽

Drug Conjugate ◽

Non Hodgkin Lymphoma ◽

Antibody Drug

Download Full-text

Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study

The Lancet Oncology ◽

10.1016/s1470-2045(15)70128-2 ◽

2015 ◽

Vol 16 (6) ◽

pp. 704-715 ◽

Cited By ~ 134

Author(s):

Maria Corinna A Palanca-Wessels ◽

Myron Czuczman ◽

Gilles Salles ◽

Sarit Assouline ◽

Laurie H Sehn ◽

...

Keyword(s):

Chronic Lymphocytic Leukaemia ◽

B Cell ◽

Hodgkin Lymphoma ◽

Lymphocytic Leukaemia ◽

Phase 1 ◽

Antibody Drug Conjugate ◽

Phase 1 Study ◽

Drug Conjugate ◽

Non Hodgkin Lymphoma ◽

Antibody Drug

Download Full-text

Objective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin lymphoma

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.8526 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 8526-8526 ◽

Cited By ~ 22

Author(s):

A. Younes ◽

A. Forero-Torres ◽

N. L. Bartlett ◽

J. P. Leonard ◽

B. Rege ◽

...

Keyword(s):

Phase I ◽

Hodgkin Lymphoma ◽

Dose Escalation ◽

Antibody Drug Conjugate ◽

Dose Escalation Study ◽

Drug Conjugate ◽

Refractory Hodgkin Lymphoma ◽

Antibody Drug

Download Full-text

Abstract 2709: Evaluation of CD37 expression and binding of AGS67E, an antibody-drug conjugate (ADC) against CD37, on white blood cells (WBCs) collected from phase I non-Hodgkin lymphoma (NHL) patients

10.1158/1538-7445.am2017-2709 ◽

2017 ◽

Author(s):

Sher Karki ◽

Hector Avina ◽

Jacqueline Lackey ◽

Ahmed Sawas ◽

Kerry J. Savage ◽

...

Keyword(s):

Phase I ◽

Hodgkin Lymphoma ◽

Blood Cells ◽

White Blood Cells ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Non Hodgkin Lymphoma ◽

Antibody Drug

Download Full-text

Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.8526 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8526-8526 ◽

Cited By ~ 5

Author(s):

Anastasios Stathis ◽

Kami J. Maddocks ◽

Ian Flinn ◽

Alex Mejia ◽

Maria Lia Palomba ◽

...

Keyword(s):

Phase I ◽

Hodgkin Lymphoma ◽

Adult Patients ◽

Antibody Drug Conjugate ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Drug Conjugate ◽

Non Hodgkin Lymphoma ◽

Antibody Drug

Download Full-text

A novel antibody–drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity

Journal of Drug Targeting ◽

10.3109/1061186x.2015.1055568 ◽

2015 ◽

Vol 24 (1) ◽

pp. 47-57 ◽

Cited By ~ 2

Author(s):

Linlin Jiang ◽

Ming Yang ◽

Xiaoyun Zhang ◽

Shiqi Bao ◽

Li Ma ◽

...

Keyword(s):

B Cell ◽

Anticancer Activity ◽

Hodgkin Lymphoma ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Non Hodgkin Lymphoma ◽

Antibody Drug

Download Full-text

Abstract PS10-51: TAA013 a trastuzumab antibody drug conjugate phase I dose escalation study in recurrent her2 positive breast cancer

10.1158/1538-7445.sabcs20-ps10-51 ◽

2021 ◽

Author(s):

J M Liu ◽

Y M Yin ◽

Hao Wu ◽

W Li ◽

X Huang ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Dose Escalation ◽

Antibody Drug Conjugate ◽

Her2 Positive ◽

Dose Escalation Study ◽

Drug Conjugate ◽

Her2 Positive Breast Cancer ◽

Antibody Drug ◽

Positive Breast Cancer

Download Full-text